Pharmacological treatment and prevention of heart failure in the diabetic patient

Reviews in Cardiovascular Medicine

Volumn 5, Issue 1, 2004, Pages 1-8

  Nesto, Richard W ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

blockers; ACE inhibitors; Diabetes; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; PINDOLOL; PROPRANOLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; CORONARY BLOOD VESSEL; COUGHING; DIABETES MELLITUS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; IMPAIRED GLUCOSE TOLERANCE; MORTALITY; PROGNOSIS; REVIEW; RISK FACTOR; STROKE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETIC ANGIOPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; INDOLES; LOSARTAN; RISK FACTORS;

EID: 1542712520     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association; 2000.
2. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
3. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:1017-1020.
4. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014-1019.
5. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18:708-714.
6. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J. 1989;118(5 Pt 1):1000-1012.
7. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990;82:848-855.
8. Lavine SJ, Gellman SD. Treatment of heart failure in patients with diabetes mellitus. Drugs. 2002;62:285-307.
9. Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99:1265-1270.
10. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
11. The CONSENSUS Trial Study Group. Effects o enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
14. Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: Data from the GISSI-3 study. Circulation. 1997;96:4239-4245.
15. Gustafsson I. Torp-Pedersen C, Køber L, et al. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol. 1999, 34:83-89.
16. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study And MICRO-HOPE substudy. Lancet. 2000;355:253-259.
17. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation. 2001;104:1985-1991.
18. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
20. Pfeffer MA, McMurray JJ, Velazquez EJ, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
21. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
22. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-1886.
23. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983;250:2814-2819.
24. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
25. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
26. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
27. Sheu WH, Swislocki AL, Hoffman B, et al. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. Am J Hypertens. 1991;4(3 Pt 1):199-205.
28. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990; 11:43-50.
29. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol. 1996;77:1273-1277.
30. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior Tyocardial infarction and diabetes mellitus. Am J Cardiol. 2001;87:780-781.
31. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295-1302.
32. Bell DS. Treatment of heart failure in patients with diabetes: Clinical update. Ethn Dis. 2002;12:S1-S8.
33. Anonymous. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J. 1983;4:367-375.
34. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955-959.
35. Younis N, Burnham P, Patwala A, et al. Beta blocker prescribing differences in patients with and without diabetes following a first myocardial infarction. Diabet Med. 2001;18:159-161.